chr9-5126715-A-G
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_004972.4(JAK2):āc.3323A>Gā(p.Asn1108Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00328 in 1,610,826 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N1108K) has been classified as Uncertain significance.
Frequency
Consequence
NM_004972.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
JAK2 | NM_004972.4 | c.3323A>G | p.Asn1108Ser | missense_variant | 25/25 | ENST00000381652.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
JAK2 | ENST00000381652.4 | c.3323A>G | p.Asn1108Ser | missense_variant | 25/25 | 1 | NM_004972.4 | P1 | |
INSL6 | ENST00000649639.1 | c.*11-2204T>C | intron_variant | ||||||
JAK2 | ENST00000487310.1 | n.514A>G | non_coding_transcript_exon_variant | 2/2 | 2 |
Frequencies
GnomAD3 genomes AF: 0.00207 AC: 314AN: 151750Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00198 AC: 494AN: 250064Hom.: 0 AF XY: 0.00206 AC XY: 279AN XY: 135228
GnomAD4 exome AF: 0.00341 AC: 4968AN: 1458958Hom.: 8 Cov.: 29 AF XY: 0.00329 AC XY: 2389AN XY: 725822
GnomAD4 genome AF: 0.00207 AC: 314AN: 151868Hom.: 0 Cov.: 32 AF XY: 0.00191 AC XY: 142AN XY: 74268
ClinVar
Submissions by phenotype
not provided Benign:2
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | JAK2: BP4, BS1 - |
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Jan 29, 2024 | - - |
not specified Benign:1Other:1
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | May 27, 2021 | - - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Thrombocythemia 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Feb 10, 2020 | This JAK2 variant (rs142269166) is present in a large population datasets (gnomAD: 552/281382 total alleles; 0.1962%; no homozygotes), but believed to be overrepresented in patients with myeloproliferative neoplasms. Bioinformatic tools queried predict that the substitution would be tolerated, but these algorithms have low specificity, especially for predicting gain of function variants. Due to lack of segregation and functional data, we consider the clinical significance of c.3323A>G to be uncertain at this time. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at